985 related articles for article (PubMed ID: 27793510)
41. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City.
Quale J; Shah N; Kelly P; Babu E; Backer M; Rosas-Garcia G; Salamera J; George A; Bratu S; Landman D
Microb Drug Resist; 2012 Apr; 18(2):132-6. PubMed ID: 22196342
[TBL] [Abstract][Full Text] [Related]
42. Colistin pharmacokinetics: the fog is lifting.
Couet W; Grégoire N; Marchand S; Mimoz O
Clin Microbiol Infect; 2012 Jan; 18(1):30-9. PubMed ID: 21988234
[TBL] [Abstract][Full Text] [Related]
43. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies.
Oliota AF; Penteado ST; Tonin FS; Fernandez-Llimos F; Sanches AC
Diagn Microbiol Infect Dis; 2019 May; 94(1):41-49. PubMed ID: 30635223
[TBL] [Abstract][Full Text] [Related]
44. Clinical Use of Polymyxin B.
Rigatto MH; Falci DR; Zavascki AP
Adv Exp Med Biol; 2019; 1145():197-218. PubMed ID: 31364080
[TBL] [Abstract][Full Text] [Related]
45. Colistin and its role in the Era of antibiotic resistance: an extended review (2000-2019).
El-Sayed Ahmed MAE; Zhong LL; Shen C; Yang Y; Doi Y; Tian GB
Emerg Microbes Infect; 2020 Dec; 9(1):868-885. PubMed ID: 32284036
[TBL] [Abstract][Full Text] [Related]
46. Potential Toxicity of Polymyxins in Human Lung Epithelial Cells.
Ahmed MU; Velkov T; Lin YW; Yun B; Nowell CJ; Zhou F; Zhou QT; Chan K; Azad MAK; Li J
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28416543
[TBL] [Abstract][Full Text] [Related]
47. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins.
van der Heijden IM; Levin AS; De Pedri EH; Fung L; Rossi F; Duboc G; Barone AA; Costa SF
Ann Clin Microbiol Antimicrob; 2007 Aug; 6():8. PubMed ID: 17697363
[TBL] [Abstract][Full Text] [Related]
48. Molecular mechanisms of polymyxin resistance: knowns and unknowns.
Baron S; Hadjadj L; Rolain JM; Olaitan AO
Int J Antimicrob Agents; 2016 Dec; 48(6):583-591. PubMed ID: 27524102
[TBL] [Abstract][Full Text] [Related]
49. Colistin: an update on the antibiotic of the 21st century.
Biswas S; Brunel JM; Dubus JC; Reynaud-Gaubert M; Rolain JM
Expert Rev Anti Infect Ther; 2012 Aug; 10(8):917-34. PubMed ID: 23030331
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics of the Individual Major Components of Polymyxin B and Colistin in Rats.
Sivanesan S; Roberts K; Wang J; Chea SE; Thompson PE; Li J; Nation RL; Velkov T
J Nat Prod; 2017 Jan; 80(1):225-229. PubMed ID: 28080060
[TBL] [Abstract][Full Text] [Related]
51. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections.
Huang J; Tang YQ; Sun JY
Scand J Infect Dis; 2010 Apr; 42(4):260-5. PubMed ID: 20085424
[TBL] [Abstract][Full Text] [Related]
52. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
[TBL] [Abstract][Full Text] [Related]
53. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).
Tsuji BT; Pogue JM; Zavascki AP; Paul M; Daikos GL; Forrest A; Giacobbe DR; Viscoli C; Giamarellou H; Karaiskos I; Kaye D; Mouton JW; Tam VH; Thamlikitkul V; Wunderink RG; Li J; Nation RL; Kaye KS
Pharmacotherapy; 2019 Jan; 39(1):10-39. PubMed ID: 30710469
[TBL] [Abstract][Full Text] [Related]
54. Polymyxin B nonapeptide potentiates the eradication of Gram-negative bacterial persisters.
Kim SJ; Jo J; Kim J; Ko KS; Lee W
Microbiol Spectr; 2024 Apr; 12(4):e0368723. PubMed ID: 38391225
[TBL] [Abstract][Full Text] [Related]
55. Colistin: understanding and applying recent pharmacokinetic advances.
Ortwine JK; Kaye KS; Li J; Pogue JM
Pharmacotherapy; 2015 Jan; 35(1):11-6. PubMed ID: 25187500
[TBL] [Abstract][Full Text] [Related]
56. Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'.
Velkov T; Roberts KD; Nation RL; Wang J; Thompson PE; Li J
ACS Chem Biol; 2014 May; 9(5):1172-7. PubMed ID: 24601489
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of susceptibility testing methods for polymyxin.
Behera B; Mathur P; Das A; Kapil A; Gupta B; Bhoi S; Farooque K; Sharma V; Misra MC
Int J Infect Dis; 2010 Jul; 14(7):e596-601. PubMed ID: 20045367
[TBL] [Abstract][Full Text] [Related]
58. Colistin: still a lifesaver for the 21st century?
Karaiskos I; Souli M; Galani I; Giamarellou H
Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):59-71. PubMed ID: 27573251
[TBL] [Abstract][Full Text] [Related]
59. Bioanalysis and Stability of Polymyxins.
Milne RW
Adv Exp Med Biol; 2019; 1145():73-87. PubMed ID: 31364072
[TBL] [Abstract][Full Text] [Related]
60. Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers.
Keirstead ND; Wagoner MP; Bentley P; Blais M; Brown C; Cheatham L; Ciaccio P; Dragan Y; Ferguson D; Fikes J; Galvin M; Gupta A; Hale M; Johnson N; Luo W; McGrath F; Pietras M; Price S; Sathe AG; Sasaki JC; Snow D; Walsky RL; Kern G
Toxicol Sci; 2014 Feb; 137(2):278-91. PubMed ID: 24189134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
